<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02202772</url>
  </required_header>
  <id_info>
    <org_study_id>AAAM8506</org_study_id>
    <nct_id>NCT02202772</nct_id>
  </id_info>
  <brief_title>Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder</brief_title>
  <acronym>CGC</acronym>
  <official_title>A Phase I Trial for the Use of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment of BCG-Refractory Non-muscle Invasive Urothelial Carcinoma of the Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>James M. McKiernan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators intend to evaluate the safety and toxicity proﬁle of intravesically&#xD;
      administered multidrug regimen of Cabazitaxel, Cisplatin and Gemcitabine in treatment&#xD;
      refractory Transitional Cell Carcinoma.The investigators propose to conduct a combined phase&#xD;
      I trial to assess the safety, toxicity, and efﬁcacy of a novel multidrug intravesical regimen&#xD;
      consisting of Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the treatment of BCG resistant&#xD;
      non-muscle invasive urothelial carcinoma of the bladder. This phase I trial will have a&#xD;
      combined dose and cycle-escalation scheme with enrollment of up to 24 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nonsurgical treatment strategies for BCG refractory bladder cancer have failed to prove&#xD;
      themselves as reliable options for increased survival among this subset of bladder cancer&#xD;
      patients. For these patients, removal of the bladder with all the associated perioperative&#xD;
      risks and the subsequent reduction of quality of life, remains the only option. Prior&#xD;
      attempts at second line treatments have included intravesical (within the bladder)&#xD;
      monotherapy with a range of drugs including Gemcitabine and Paclitaxel (a taxane, similar to&#xD;
      Cabazitaxel). These drugs have shown some potential improvement for a small number of&#xD;
      patients Given the synergy of systemic chemotherapy, it is believed that a multidrug regimen&#xD;
      would allow for further improvement in survival among these patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">December 1, 2014</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of serious adverse events associated with therapy of intravesically administered Cabazitaxel, Gemcitabine, and Cisplatin.</measure>
    <time_frame>6 weeks from baseline</time_frame>
    <description>The investigator is measuring safety by looking at the number of events that occur during the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of complete responders after completion of six weeks of intravesically administered Cabazitaxel, Gemcitabine, and Cisplatin.</measure>
    <time_frame>6 weeks from baseline</time_frame>
    <description>The investigator is measuring efficacy by the number of complete responders to the treatment</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Urothelial Carcinoma of the Urinary Bladder</condition>
  <arm_group>
    <arm_group_label>Gem and Low Cab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 2.5mg/100ml; 1 time a week for 6 weeks; 2 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gem and High Cab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gem, High Cab, and Low Cis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 66mg/100ml; 1 time a week for 6 weeks; 2 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gem, High Cab, Mod Cis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 80mg/100ml; 1 time a week for 6 weeks; 2 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gem, High Cab, High Cis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 100mg/100ml; 1 time a week for 6 weeks; 2 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabazitaxel</intervention_name>
    <description>Intravesical instillation of the Cabazitaxel for 2 hours</description>
    <arm_group_label>Gem and High Cab</arm_group_label>
    <arm_group_label>Gem and Low Cab</arm_group_label>
    <arm_group_label>Gem, High Cab, High Cis</arm_group_label>
    <arm_group_label>Gem, High Cab, Mod Cis</arm_group_label>
    <arm_group_label>Gem, High Cab, and Low Cis</arm_group_label>
    <other_name>Jevtana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Intravesical instillation of Gemcitabine for 2 hours</description>
    <arm_group_label>Gem and High Cab</arm_group_label>
    <arm_group_label>Gem and Low Cab</arm_group_label>
    <arm_group_label>Gem, High Cab, High Cis</arm_group_label>
    <arm_group_label>Gem, High Cab, Mod Cis</arm_group_label>
    <arm_group_label>Gem, High Cab, and Low Cis</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Intravesical installation of Cisplatin for 2hours</description>
    <arm_group_label>Gem, High Cab, High Cis</arm_group_label>
    <arm_group_label>Gem, High Cab, Mod Cis</arm_group_label>
    <arm_group_label>Gem, High Cab, and Low Cis</arm_group_label>
    <other_name>Platinol, Platinol-AQ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must have a histologically confirmed diagnosis of non- muscle invasive urothelial&#xD;
        carcinoma of the bladder at the study institution prior to the beginning of the study. This&#xD;
        includes patients with:&#xD;
&#xD;
          -  High grade Ta papillary lesion(s)&#xD;
&#xD;
          -  High or low grade T1 papillary lesion(s)&#xD;
&#xD;
          -  Carcinoma In Situ (CIS), with or without Ta or T1 papillary tumor(s) of any grade The&#xD;
             patient must have Bacillus Calmette-Guerin (BCG) refractory or recurrent non-muscle&#xD;
             invasive bladder cancer&#xD;
&#xD;
          -  Refractory disease is defined as evidence of persistent high risk bladder cancer (high&#xD;
             grade Ta, T1 and/or CIS) at the first cystoscopic exam after the initial 6 week&#xD;
             induction course of BCG or at the 6 month cystoscopic exam.&#xD;
&#xD;
          -  Recurrent disease is defined as reappearance of disease after achieving a tumor- free&#xD;
             status by 6 months following a full induction course of BCG with or without&#xD;
             maintenance BCG. Participants must have recurred within 18 months following the last&#xD;
             dose of BCG.&#xD;
&#xD;
               -  Low-grade superficial (Ta) disease will not be considered recurrent.&#xD;
&#xD;
               -  Patients must exhibit disease recurrence after receiving some form of standard&#xD;
                  intravesical therapy that must include a minimum of one induction course of BCG&#xD;
                  and may also include prior exposure to mitomycin, interferon, single agent&#xD;
                  gemcitabine or taxane therapy or maintenance.&#xD;
&#xD;
          -  Patients must be eligible for radical cystectomy and refuse this standard of care&#xD;
             treatment or not be a surgical candidate for radical cystectomy based on other&#xD;
             comorbidities.&#xD;
&#xD;
          -  All grossly visible disease in the bladder must be fully resected and pathologic stage&#xD;
             will be confirmed at the study institution.&#xD;
&#xD;
          -  Patients enrolled in other clinical trials must have received their last treatment at&#xD;
             least 6 weeks prior to enrollment.&#xD;
&#xD;
          -  Age &gt; 18 and must be able to read, understand and sign informed consent&#xD;
&#xD;
          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance Status:&#xD;
             ECOG of 0 or 1 including patients who are not surgical candidates due to comorbid&#xD;
             conditions.&#xD;
&#xD;
          -  Peripheral neuropathy: must be &lt; grade 1&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test.&#xD;
&#xD;
          -  All patients of childbearing potential must be willing to consent to using effective&#xD;
             contraception, i.e., intrauterine device (IUD), Birth control pills, Depo-Provera, and&#xD;
             condoms while on treatment and for 3 months after their participation in the study&#xD;
             ends.&#xD;
&#xD;
          -  No experimental intravesical therapy within 6 weeks of study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of severe hypersensitivity reaction (≥grade 3) to docetaxel&#xD;
&#xD;
          -  History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing&#xD;
             drugs&#xD;
&#xD;
          -  Concurrent or planned treatment with strong inhibitors or strong inducers of&#xD;
             cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who are&#xD;
             already on I these treatments)&#xD;
&#xD;
          -  Concurrent malignancy diagnosed within 6 months of entry to the study.&#xD;
&#xD;
          -  Concurrent treatment with any systemic chemotherapeutic agent.&#xD;
&#xD;
          -  Inadequate organ and bone marrow function as evidenced by:&#xD;
&#xD;
               -  Hemoglobin: less than 8.0 g/dL&#xD;
&#xD;
               -  Absolute neutrophil count: less than 1.5 x 10^9/L&#xD;
&#xD;
               -  Platelet count: less than 80x 10^9/L&#xD;
&#xD;
               -  Aspartate Aminotransferase Test (AST) / Serum Glutamic Oxaloacetic Transaminase&#xD;
                  (SGOT) and/or ( Alanine Aminotransferase Test (ALT)/ Serum Glutamic Pyruvic&#xD;
                  Transaminase (SGPT) &gt;2.5 x upper limit of normal (ULN);&#xD;
&#xD;
               -  Total bilirubin &gt;1.0 x ULN&#xD;
&#xD;
               -  Serum creatinine &gt;2 x ULN. If creatinine 1.5 - 2.0 x ULN, creatinine clearance&#xD;
                  will be calculated according to Chronic Kidney Disease Epidemiology Collaboration&#xD;
                  (CKD-EPI) formula and patients with creatinine clearance &lt;30 mL/min should be&#xD;
                  excluded.&#xD;
&#xD;
          -  Women who are pregnant or lactating.&#xD;
&#xD;
          -  Documented history of vesicoureteral reflux or an indwelling urinary stent.&#xD;
&#xD;
          -  Participation in any other research protocol involving administration of an&#xD;
             investigational agent within 6 weeks prior to study entry.&#xD;
&#xD;
          -  No Institutional Review Board (IRB) approved signed consent form&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guarionex DeCastro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center- HIP</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://hiccc.columbia.edu/clinicaltrials/</url>
    <description>Columbia University current clinical trials</description>
  </link>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>July 25, 2014</study_first_submitted>
  <study_first_submitted_qc>July 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2014</study_first_posted>
  <last_update_submitted>June 26, 2018</last_update_submitted>
  <last_update_submitted_qc>June 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>James M. McKiernan</investigator_full_name>
    <investigator_title>Chairman of Urology</investigator_title>
  </responsible_party>
  <keyword>Urothelial</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Cabazitaxel</keyword>
  <keyword>Bladder</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Bacillus Calmette-Guerin</keyword>
  <keyword>Intravesical</keyword>
  <keyword>Recurrent</keyword>
  <keyword>Non-muscle</keyword>
  <keyword>Invasive</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT02202772/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

